Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 580

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 580
---
 2024 based on capital requirements, and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost bases. Non-cash Interest Expense on Liability Related to the Sales of Future Royalties and Milestones

| ​                                                                                         
 ​                                                                                         | ​ 
 ​ | ​ 
 ​ | Year Ended December 31,     
 2023                        |   |      |   |   |   |          |   |     |   | ​ | ​ | 2022 |   |   |   |   |   |          |   |     |   | ​ 
 ​ |
|:------------------------------------------------------------------------------------------|:--|:--|:----------------------------|:--|-----:|:--|:--|:--|:---------|:--|:----|:--|:--|:--|:-----|:--|:--|:--|:--|:--|:---------|:--|:----|:--|:--|
| ​                                                                                         | ​ | ​ | Dollar amounts in thousands |   |      |   |   |   |          |   |     |   |   |   |      |   |   |   |   |   |          |   |     |   | ​ |
| ​                                                                                         | ​ | ​ | ​                           | ​ |    ​ | ​ | ​ | ​ | % change |   |     |   | ​ | ​ | ​    | ​ | ​ | ​ | ​ | ​ | % change |   |     |   | ​ |
| Non-cash interest expense on liability related to sales of future royaltiesand milestones | ​ | ​ | ​                           | $ | -604 | ​ | ​ | ​ | ​        | ​ | N/A | ​ | ​ | ​ | ​    | $ | — | ​ | ​ | ​ | ​        | ​ | N/A | ​ | ​ |

We recognized $0.6 million of non-cash interest expense on the liability related to sales of future royalties and milestones for the year ended December 31, 2023, which represented imputed interest on the carrying value of the liability to HCR in the fourth quarter of 2023 and the amortization of the related issuance costs associated with the HCR Agreement. There was no non-cash interest expense on liability recognized during the year ended December 31, 2022 as the HCR Agreement was entered into in November 2023 (